Literature DB >> 33342268

Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes.

Christof Kaltenmeier1, Alison Althans1, Maria Mascara1, Ibrahim Nassour1, Sidrah Khan1, Richard Hoehn1, Amer Zureikat1, Samer Tohme1.   

Abstract

INTRODUCTION: With advances in multimodal therapy, survival rates in gastric cancer have significantly improved over the last two decades. Neoadjuvant therapy increases the likelihood of achieving negative margins and may even lead to pathologic complete response (pCR). However, the impact of pCR on survival in gastric cancer has been poorly described. We analyzed the rate and predictors of pCR in patients receiving neoadjuvant therapy as well as impact of pCR on survival.
METHODS: We conducted a National Cancer Database (NCDB) analysis (2004-2016) of patients with gastric adenocarcinoma who received neoadjuvant chemotherapy followed by surgical resection.
RESULTS: The pCR rate was 2.2%. Following adjustment, only neoadjuvant chemoradiation, non-signet histology, and tumor grade remained as significant factors predicting pCR. pCR was a statistically significant predictor of survival.
CONCLUSION: In this NCDB study, pCR was a predictor of survival. Though chemoradiation rather than chemotherapy alone was a predictor of pCR, it was not a predictor of survival. Further studies are needed to elucidate the role of radiation in the neoadjuvant setting and to discern the impact of pCR on survival.

Entities:  

Keywords:  esophagus/foregut; surgical oncology

Year:  2020        PMID: 33342268      PMCID: PMC8213860          DOI: 10.1177/0003134820972083

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  24 in total

1.  Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A).

Authors:  Yukinori Kurokawa; Taro Shibata; Mitsuru Sasako; Takeshi Sano; Akira Tsuburaya; Yoshiaki Iwasaki; Haruhiko Fukuda
Journal:  Gastric Cancer       Date:  2013-09-03       Impact factor: 7.370

Review 2.  Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.

Authors:  Parisa Karimi; Farhad Islami; Sharmila Anandasabapathy; Neal D Freedman; Farin Kamangar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-11       Impact factor: 4.254

3.  TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.

Authors:  Trevor Leong; B Mark Smithers; Karin Haustermans; Michael Michael; Val Gebski; Danielle Miller; John Zalcberg; Alex Boussioutas; Michael Findlay; Rachel L O'Connell; Jaclyn Verghis; David Willis; Tomas Kron; Melissa Crain; William K Murray; Florian Lordick; Carol Swallow; Gail Darling; John Simes; Rebecca Wong
Journal:  Ann Surg Oncol       Date:  2017-03-23       Impact factor: 5.344

4.  Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.

Authors:  Jaffer A Ajani; Kathryn Winter; Gordon S Okawara; John H Donohue; Peter W T Pisters; Christopher H Crane; John F Greskovich; P Rani Anne; Jeffrey D Bradley; Christopher Willett; Tyvin A Rich
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

5.  Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Nils Homann; Claudia Pauligk; Thorsten O Goetze; Johannes Meiler; Stefan Kasper; Hans-Georg Kopp; Frank Mayer; Georg Martin Haag; Kim Luley; Udo Lindig; Wolff Schmiegel; Michael Pohl; Jan Stoehlmacher; Gunnar Folprecht; Stephan Probst; Nicole Prasnikar; Wolfgang Fischbach; Rolf Mahlberg; Jörg Trojan; Michael Koenigsmann; Uwe M Martens; Peter Thuss-Patience; Matthias Egger; Andreas Block; Volker Heinemann; Gerald Illerhaus; Markus Moehler; Michael Schenk; Frank Kullmann; Dirk M Behringer; Michael Heike; Daniel Pink; Christian Teschendorf; Carmen Löhr; Helga Bernhard; Gunter Schuch; Volker Rethwisch; Ludwig Fischer von Weikersthal; Jörg T Hartmann; Michael Kneba; Severin Daum; Karsten Schulmann; Jörg Weniger; Sebastian Belle; Timo Gaiser; Fuat S Oduncu; Martina Güntner; Wael Hozaeel; Alexander Reichart; Elke Jäger; Thomas Kraus; Stefan Mönig; Wolf O Bechstein; Martin Schuler; Harald Schmalenberg; Ralf D Hofheinz
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

6.  Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.

Authors:  Angelita Habr-Gama; Rodrigo Oliva Perez; Wladimir Nadalin; Jorge Sabbaga; Ulysses Ribeiro; Afonso Henrique Silva e Sousa; Fábio Guilherme Campos; Desidério Roberto Kiss; Joaquim Gama-Rodrigues
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

7.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

Authors:  Joel Tepper; Mark J Krasna; Donna Niedzwiecki; Donna Hollis; Carolyn E Reed; Richard Goldberg; Krystyna Kiel; Christopher Willett; David Sugarbaker; Robert Mayer
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

8.  Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer.

Authors:  Tamer Soror; Gerlinda Kho; Kuai-Le Zhao; Mahmoud Ismail; Harun Badakhshi
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

9.  The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer.

Authors:  Nikhil Waingankar; Rachel Jia; Kathryn E Marqueen; Francois Audenet; John P Sfakianos; Reza Mehrazin; Bart S Ferket; Madhu Mazumdar; Matthew D Galsky
Journal:  Urol Oncol       Date:  2019-05-18       Impact factor: 2.954

10.  Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.

Authors:  Ziyu Li; Fei Shan; Yinkui Wang; Yan Zhang; Lianhai Zhang; Shuangxi Li; Yongning Jia; Kan Xue; Rulin Miao; Zhemin Li; Jiafu Ji
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

View more
  2 in total

1.  A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer.

Authors:  Eric Anderson; Alexis LeVee; Sungjin Kim; Katelyn Atkins; Michelle Guan; Veronica Placencio-Hickok; Natalie Moshayedi; Andrew Hendifar; Arsen Osipov; Alexandra Gangi; Miguel Burch; Kevin Waters; May Cho; Samuel Klempner; Joseph Chao; Mitchell Kamrava; Jun Gong
Journal:  JAMA Netw Open       Date:  2021-12-01

Review 2.  Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives.

Authors:  Nikolaos Charalampakis; Sergios Tsakatikas; Dimitrios Schizas; Stylianos Kykalos; Maria Tolia; Rodanthi Fioretzaki; Georgios Papageorgiou; Ioannis Katsaros; Ahmed Adel Fouad Abdelhakeem; Matheus Sewastjanow-Silva; Jane E Rogers; Jaffer A Ajani
Journal:  World J Gastrointest Oncol       Date:  2022-01-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.